Stock Financial Ratios, Dividends, Split History

TNDM / Tandem Diabetes Care, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,217.65
Enterprise Value ($M)1,211.64
Book Value ($M)11.85
Book Value / Share0.24
Price / Book102.77
NCAV ($M)-18.51
NCAV / Share-0.37
Price / NCAV-68.85
Share Statistics
Common Shares Outstanding 44,699,404
Common Stock Shares Outstanding 10,119,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.36
Return on Assets (ROA)-0.65
Return on Equity (ROE)12.32
Balance Sheet (mrq) ($M)
Quick Ratio2.01
Current Ratio2.62
Income Statement (mra) ($M)
Sales Revenue Net107,601,000.00
Future Minimum Annual Revenues Attainable In Current80,000,000.00
Future Minimum Annual Revenues Attainable Thereafter95,000,000.00
Operating Income-62.94
Net Income-73.03
Earnings Per Share Basic And Diluted-12.87
Cash Flow Statement (mra) ($M)
Cash From Operations-66.14
Cash from Investing2.78
Cash from Financing-66.14
Identifiers and Descriptors
Central Index Key (CIK)1438133
Related CUSIPS
875372904 875372954

Split History

Stock splits are used by Tandem Diabetes Care, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
TNDM: Tandem Diabetes Care Analysis and Research Report

2018-02-10 - Asif

Tandem Diabetes Care is a medical device company with an innovative approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The company believe that its competitive advantage is rooted in its unique consumer-focused approach and proprietary technology platform. This allows it to deliver innovative hardware and software solutions to meet the various needs and preferences of people with diabetes and their healthcare providers. The company manufacture and sell insulin pump products in the United States that are designed to address large and differentiated segments of the insulin-dependent diabetes market. The company's insulin pump products include: the t:slim X2 Insulin Delivery System, or t:slim X2, its next-generation flagship product that is updatable and designed to display Dexcom G5 continuous glucose monitoring, or CGM, sensor information directly on the pump Home Screen; and the t:flex Insulin Delivery System, or ...

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

Your Daily Pharma Scoop: Heron Spikes, Ironwood Pharma Moves Ahead, Mesoblast Positive

2018-06-27 seekingalpha
The Daily Scoop is going to turn one year soon. Thank you for reading, commenting, and supporting our efforts. Please go to the end of this article to read an important announcement. (148-2)

Why Tandem Stock Could Continue Its Rally | InvestorPlace

2018-06-25 investorplace
If you’ve been with Tandem Diabetes Care (NASDAQ:TNDM) since in the early innings of its massive rally in April, you really enjoyed the over 13 percent rally on Friday. The main cause was the FDA approval of Tandem’s t:slim X2 Insulin Pump with Basal-IQ. (69-2)

Epic Rally In Tandem Diabetes Care, Can It Continue?

2018-06-25 seekingalpha
A magnificent share rally in Tandem Diabetes Care has ensued this year as it became clear to investors that the company isn't going belly-up. (29-1)

Tandem Diabetes Keeps Rolling Out the Hits

2018-06-22 247wallst
Tandem Diabetes Care Inc. (NASDAQ: TNDM) shares made a solid gain early on Friday after the firm announced a key approval from the U.S. Food and Drug Administration (FDA). (24-1)

After hours buzz: RHT, CMC & more

2018-06-21 cnbc
Shares of Red Hat plummeted more than 11 percent in extended-hours trading, after the company reported better than expected first quarter earnings and revenue, but reported weak guidance. The software company earned 72 cents per share, beating analyst estimates of 69 cents per share. Red Hat also beat revenue estimates of $807 million, instead posting $814 million. (30-1)

CUSIP: 875372104